215 related articles for article (PubMed ID: 22101555)
21. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.
Díaz-Lagares C; Croca S; Sangle S; Vital EM; Catapano F; Martínez-Berriotxoa A; García-Hernández F; Callejas-Rubio JL; Rascón J; D'Cruz D; Jayne D; Ruiz-Irastorza G; Emery P; Isenberg D; Ramos-Casals M; Khamashta MA;
Autoimmun Rev; 2012 Mar; 11(5):357-64. PubMed ID: 22032879
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
23. [Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment].
Tsanian MÉ; Solov'ev SK; Torgashina AV; Aleksandrova EN; Radenska-Lopovok SG; Nikolaeva EV; Khrennikova IaB; Nasonov EL
Ter Arkh; 2014; 86(5):40-9. PubMed ID: 25026801
[TBL] [Abstract][Full Text] [Related]
24. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
26. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus.
Pinto LF; Velásquez CJ; Prieto C; Mestra L; Forero E; Márquez JD
Lupus; 2011 Oct; 20(11):1219-26. PubMed ID: 21784778
[TBL] [Abstract][Full Text] [Related]
27. Effect of Rituximab on Serum Levels of Anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis.
Zhang J; Zhao Z; Hu X
Cell Biochem Biophys; 2015 May; 72(1):197-201. PubMed ID: 25490907
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.
Ale'ed A; Alsonbul A; Al-Mayouf SM
Rheumatol Int; 2014 Apr; 34(4):529-33. PubMed ID: 24218286
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.
Tambralli A; Beukelman T; Cron RQ; Stoll ML
J Rheumatol; 2015 Mar; 42(3):541-6. PubMed ID: 25593242
[TBL] [Abstract][Full Text] [Related]
30. Clinical manifestations, immunological features and prognosis of Chinese pediatric systemic lupus erythematosus: A single-center study.
Zhang CX; Cai L; Zhou ZY; Mao YY; Huang H; Yin L; Chen TX; Zhou W
Int J Rheum Dis; 2019 Jun; 22(6):1070-1076. PubMed ID: 30957986
[TBL] [Abstract][Full Text] [Related]
31. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
Tanaka Y; Yamamoto K; Takeuchi T; Nishimoto N; Miyasaka N; Sumida T; Shima Y; Takada K; Matsumoto I; Saito K; Koike T
Mod Rheumatol; 2007; 17(3):191-7. PubMed ID: 17564773
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
[TBL] [Abstract][Full Text] [Related]
33. Rituximab in Treatment of Children with Refractory Vasculitis and Systemic Lupus Erythematosus - Single Center Experience in Croatia.
Sršen S; Frković M; Malčić I; Jelušić M
Acta Dermatovenerol Croat; 2020 Aug; 28(2):63-69. PubMed ID: 32876030
[TBL] [Abstract][Full Text] [Related]
34. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.
Tanaka Y; Takeuchi T; Miyasaka N; Sumida T; Mimori T; Koike T; Endo K; Mashino N; Yamamoto K
Mod Rheumatol; 2016; 26(1):80-6. PubMed ID: 26054418
[TBL] [Abstract][Full Text] [Related]
36. Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus.
Bang SY; Lee CK; Kang YM; Kim HA; Suh CH; Chung WT; Park YB; Choe JY; Kim TJ; Park YW; Yoo DH; Bae SC; Lee HS
Autoimmune Dis; 2012; 2012():565039. PubMed ID: 23304457
[TBL] [Abstract][Full Text] [Related]
37. Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years.
Aguiar R; Araújo C; Martins-Coelho G; Isenberg D
Arthritis Care Res (Hoboken); 2017 Feb; 69(2):257-262. PubMed ID: 27110698
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
Kraaij T; Arends EJ; van Dam LS; Kamerling SWA; van Daele PLA; Bredewold OW; Ray A; Bakker JA; Scherer HU; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
Nephrol Dial Transplant; 2021 Jul; 36(8):1474-1483. PubMed ID: 32591783
[TBL] [Abstract][Full Text] [Related]
39. B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases.
Sangle SR; Lutalo PM; Davies RJ; Khamashta MA; D'Cruz DP
J Autoimmun; 2013 Jun; 43():55-9. PubMed ID: 23608146
[TBL] [Abstract][Full Text] [Related]
40. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.
Olfat M; Silverman ED; Levy DM
Lupus; 2015 Aug; 24(9):966-72. PubMed ID: 25804672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
